Tech transfer The Swedish Context. Academia-industry collaboration. .. Created the largest selling drug, LOSEC, followed by Nexium

Size: px

Start display at page:

Download "Tech transfer The Swedish Context. Academia-industry collaboration. .. Created the largest selling drug, LOSEC, followed by Nexium"

Felicia Poole
8 years ago
Views:

1 Tech transfer The Swedish Context Claes Post, May , Brussels Academia-industry collaboration Scand J Gastroenterol Suppl. 1989;166:3-11.The gastric H+,K+- ATPase: the site of action of omeprazole.sachs G, Wallmark B.CURE Foundation, Veterans Administration Centre, West Los Angeles. Gastroenterology Dec;95(6): Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.larsson H, Carlsson E, Håkanson R, Mattsson H, Nilsson G, Seensalu R, Wallmark B, Sundler F.Department of Biology, AB Hässle, Mölndal, Sweden... Created the largest selling drug, LOSEC, followed by Nexium Ivan Östholm, head of research at Hässle (ASTRA subsidiary), instrumental for the success of LOSEC

Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.

2 Lidocaine (Löfgren and Lundqvist) Astra Beta-blocker (Arvid Carlsson) - Astra Separation products (Jerker Porath) - Pharmacia Nuclear receptors- (Jan-Åke Gustafsson) KaroBio Endogenous oipiods Lars Terenius Implement Karolinska Institutet innovation system Hans Wigzell Other examples.. And the presence of Big Pharma and Med tech Cluster, e.g. Stockholm- Uppsala Employees in different fields: Drug Development & Production: 11,801 Medical Technology: 3,023 Biotech Tools and Supplies: 1,659 Diagnostics: 937 Other Segments: 1,429 Total: 18,849 Companies with over 1000 employees: Astrazeneca Pfizer Health GE Healthcare Biosciences Recip Stockholm Companies with employees: Fresenius Kabi St. Jude Medical Biovitrum Advanced Medical Optics Uppsala Arvid Carlsson, MD, PhD, Professor, Nobel Laureate L-DOPA as DA precursor Beta-blockare Beta-agonister Dopamine-receptor normalizing drugs Carlsson Research AB Neurosearch

ell Other examples.. And the presence of Big

3 Svante Pääbo, PhD, Leipzig, Max Planck Dilafor Gunvor Ekman-Ordeberg,Professor and clinical obstetrician, Karolinska Institute and Karolinska University Hospital, Stockholm New low-molecular weight heparin, designed to be devoid of anticoagulant effects. Reduction of partum duration, particularly in women with prolonged delivery times. First compound in Phase II clinical development. Neopharma, Sensidose Sten-Magnus Aquilonius, Prof Em, Uppsala universiy and Christer Nyström,business man and previously at Professor Uppsala University Developed Duo-DOPA and started Neopharma AB, later sold to Solvay Pharma Germany. ). The spin-out company Sensidose AB, based on a novel dispensing technology to dose e.g. L- DOPA

First compound in Phase II clinical development.

4 OLINK Bioscience, OLINK Genomics Ulf Landegren, Professor Rudberck laboratory, Uppsala universitet Protein- och DNA methods Bioarctic Lars Lannfelt, MD, PhD, Uppsala University, discovered mutations related to Alzheimer s diseases Bioarctic Pharma develops novel methods to treat Alzheimer s deisease with active and/or passive immunization towards Almyloid beta, develops new methods to treat spinal cord injury. Partner Eisai, Japan PET-development Bengt Långström,PhD, Professor, PET-centre Uppsala and GE-Healthcare Imanet PET Centre, Uppsala Långström has developed strategies to label small molecules with PET-emitting isotopes for PET-visualization

passive immunization towards Almyloid beta, develops new methods to treat spinal cord injury.

5 Aprea Klas Wiman,PhD, Professor, CCK, Karolinska Institute Aprea develops novel compounds to treat cancer based on normalisation of mutated p53 induction of apotposis Umeå university, a few examples Creatice antibiotics, Founder Staffan Normark, PhD, Professor, Karolinska Institute New prinicples to treat bacterial infections Betagenon, Founders, Profs Helena Edlund and Thomas Edlund Novel drugs to treat obesity Umecrine, FounderTorbjörn Bäckström, Professor, Umeå university New drugs to treat CNS disorders based on modulation of GABA-receptors

Karolinska Institute New prinicples to treat bacterial infections Betagenon, Founders, Profs Helena Edlund and Thomas Edlund Novel drugs

6 Low molecular early drug projects have become difficult to finance Focus: Projects in clinical development Biopharmaceuticals or Med tech Personalized medicine genomics screen, biomarkers.. Trends Risk aversion from new targets due to high risk; IF in focus for taker high potential Upside Big Pharma increase the proportin of inlicensed projects and now? Start-up companies lack capital VC has changed focus from high risk AstraZeneca reducing R&D, total reduction in Lund Biovitrum has changed from large Biotech, LMW Pharma to Biotech/Protein company Growing redundancy in the industry, mainly in medicinal chemistry All Big Pharma companies actively seek inlicansing opportunities from academic research and small companies with aim to have at least 50% of portfolio from inlicencing Examples of Life Science inventions GENES GENE-patterns Drug TARGETS Genrs Enzymes Receptors 3D structures of targets (for In Silico drug development) TOOLS and TECHNIQUES ANIMAL MODELS SUBSTANCES, LOW- MOLECULAR WEIGHT AND BIOLOGICALS Small molecules, peptides, proteins, nucleotides, sirna; with potentill to be developed to drugs New use of known (patented or off-patent) compounds MED TECH

Start-up companies lack capital VC has changed focus from high risk AstraZeneca reducing R&D, total reduction in Lund Biovitrum has changed from large Biotech, LMW Pharma to Biotech/Protein company

7 The PATENT-PROCESS Start: PRIORITY APPLICATION ( 8.000) 12 months: PCT APPLICATION ( 8.000) 18 months: PUBLICATION ( 1000) 30 months: NATIONAL / REGIONAL ENTRY OF PCT APPLICATION (big!!) 20 years: PATENT EXPIRED Year 1 Year 2 Year 3 Money needed!! Some Swedish sources Svenska riskkapitalföreningen ALMI Almi Invest Innovationsbron VINNOVA Industrifonden Karolinska Development HealthCap CapMan Investor Growth Capital CONNECT Affärsänglar; exv STOAFF AP-fonderna Östersjöstiftelsen Praktikerinvest SLS Ventures Chalmers Invest Brainheart Första entreprenörsfonden Innovationskapital SEB Ventures Swedish university based support for innovation Innovations offices (Tech Transfer) Holding companies Forskarpatent i Uppsala AB Incubators

! Some Swedish sources Svenska riskkapitalföreningen ALMI Almi Invest Innovationsbron VINNOVA Industrifonden Karolinska Development HealthCap CapMan Investor Growth Capital CONNECT

8 Inkubatorer, IBIP Aurorum Business Incubator ABUMEÅ Biotech Incubator ABUminova Innovation Stockholm Innovation & Growth ABKarolinska Institutet Innovations ABStockholm Universitet Innovation ABLEAD LiU Entrepreneurship and DevelopmentStiftelsen TeknikdalenStiftelsen Inova i WermlandCreate Business Incubator Mälardalen AB Uppsala Innovation Centre AB Science Park Jönköping ABChalmers InnovationGothia Science ParkSahlgrenska Science ParkEncubatorGU Holding Blekinge Business IncubatorIdeon InnovationMINCLUND Bioinkubator.. With all this, can you remain as excellent scientist AND commercialize your inventions? ABSOLUTELY YES!! But seek support! University innovation system Network Commercial rights Swedish teacher s excempt ACCORDING TO THE LINKÖPING UNIVERSITY: Sideline work should be encouraged

InnovationGothia Science ParkSahlgrenska Science ParkEncubatorGU Holding Blekinge Business IncubatorIdeon InnovationMINCLUND Bioinkubator.

9 WHAT STOPS YOU? NOT INTERESTED LACKS MONEY TAKES TOO MUCH TIME DON T KNOW HOW NO INCENTIVES/UPSIDE IMPORTANT FACTORS FOR SUCCESS Excellent research University prioritizes commercialisation University innovation office/tech Transfer organisation with competent resources AND financials Societal infrastructure and available capital Scientists remain as scientists Entrepreneur develops the business Different types of entrepreneurs depending of developmental stage The innovations system/tech transfer systen do active scouting for the good projects with potential My views on the prospects? Swedish research still has a good position, but worrying lagging in the international competiotion University based Tech Transfer structure is under active build-up, but still long way to go Teacher s excempt can not be elminated until a significant increased strength has been established Big pharma, Med tech and diagnostics companies actively seeking new opportunities VC capital needed for project development in start-up companies and early development phases The future can be very succesful provided

office/tech Transfer organisation with competent resources AND financials Societal infrastructure and available capital Scientists remain as scientists Entrepreneur develops the business Different

10 Melacure Therapeutics AB SoftCure Pharmaceuticals AB Selectica Pharmaceuticals AB

The Swedish Drug Development Pipeline. December 2013. & overview of Swedish companies with R&D activities in Sweden

The Swedish Drug Development Pipeline & overview of Swedish companies with R&D activities in Sweden December 2013 This report is compiled by SwedenBIO with support from VINNOVA and Business Sweden Table